🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Recruitingn/aAges 18 Years - anyAllHoffmann-La Roche
NCT06780150 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of MS * RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024 * First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab Exclusion Criteria: * Participation in interventional studies investigating DMTs for MS * Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site * Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®) * Severe psychiatric disability * Pregnant women
💊

What it tests

  • Ocrelizumab
📍

Where

93 sites
Uniklinik RWTH Aachen
Aachen, Germany
Gesundheitszentrum St. Marien GmbH
Amberg, Germany
Sächsisches Krankenhaus Arnsdorf
Arnsdorf, Germany
Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR
Aschaffenburg, Germany
Neurologie Bad Soden
Bad Soden, Germany
Neurologische Praxis - Kallmann Neurologie - mszb
Bamberg, Germany
Marianne-Strauß-klinik
Berg, Germany
Neurologisches Facharztzentrum Berlin am Sankt Gertrauden-Krankenhaus
Berlin, Germany

…and 85 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy